94 related articles for article (PubMed ID: 19783898)
21. Bax translocation mediated mitochondrial apoptosis and caspase dependent photosensitizing effect of Ficus religiosa on cancer cells.
Haneef J; Parvathy M; Thankayyan R SK; Sithul H; Sreeharshan S
PLoS One; 2012; 7(7):e40055. PubMed ID: 22792212
[TBL] [Abstract][Full Text] [Related]
22. Combinatorial drug therapy for cancer in the post-genomic era.
Al-Lazikani B; Banerji U; Workman P
Nat Biotechnol; 2012 Jul; 30(7):679-92. PubMed ID: 22781697
[TBL] [Abstract][Full Text] [Related]
23. Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.
Troiani T; Vecchione L; Martinelli E; Capasso A; Costantino S; Ciuffreda LP; Morgillo F; Vitagliano D; D'Aiuto E; De Palma R; Tejpar S; Van Cutsem E; De Lorenzi M; Caraglia M; Berrino L; Ciardiello F
Br J Cancer; 2012 May; 106(10):1648-59. PubMed ID: 22569000
[TBL] [Abstract][Full Text] [Related]
24. Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.
Mitsiades N; Chew SA; He B; Riechardt AI; Karadedou T; Kotoula V; Poulaki V
Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7248-55. PubMed ID: 21828154
[TBL] [Abstract][Full Text] [Related]
25. The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma.
Bhalla S; Evens AM; Dai B; Prachand S; Gordon LI; Gartenhaus RB
Blood; 2011 Jul; 118(4):1052-61. PubMed ID: 21628402
[TBL] [Abstract][Full Text] [Related]
26. STAT3 mediates resistance to MEK inhibitor through microRNA miR-17.
Dai B; Meng J; Peyton M; Girard L; Bornmann WG; Ji L; Minna JD; Fang B; Roth JA
Cancer Res; 2011 May; 71(10):3658-68. PubMed ID: 21444672
[TBL] [Abstract][Full Text] [Related]
27. Deciphering the role of forkhead transcription factors in cancer therapy.
Yang JY; Hung MC
Curr Drug Targets; 2011 Aug; 12(9):1284-90. PubMed ID: 21443462
[TBL] [Abstract][Full Text] [Related]
28. Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim.
Meng J; Fang B; Liao Y; Chresta CM; Smith PD; Roth JA
PLoS One; 2010 Sep; 5(9):e13026. PubMed ID: 20885957
[TBL] [Abstract][Full Text] [Related]
29. Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer.
Yang JY; Chang CJ; Xia W; Wang Y; Wong KK; Engelman JA; Du Y; Andreeff M; Hortobagyi GN; Hung MC
Cancer Res; 2010 Jun; 70(11):4709-18. PubMed ID: 20484037
[TBL] [Abstract][Full Text] [Related]
30. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
Gopal YN; Deng W; Woodman SE; Komurov K; Ram P; Smith PD; Davies MA
Cancer Res; 2010 Nov; 70(21):8736-47. PubMed ID: 20959481
[TBL] [Abstract][Full Text] [Related]
31. Clinical Development of BRAF plus MEK Inhibitor Combinations.
Subbiah V; Baik C; Kirkwood JM
Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
[TBL] [Abstract][Full Text] [Related]
32. Roles of protein kinase B/Akt in lung cancer.
Xu CX; Jin H; Shin JY; Kim JE; Cho MH
Front Biosci (Elite Ed); 2010 Jun; 2(4):1472-84. PubMed ID: 20515818
[TBL] [Abstract][Full Text] [Related]
33. High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886).
Meng J; Peng H; Dai B; Guo W; Wang L; Ji L; Minna JD; Chresta CM; Smith PD; Fang B; Roth JA
Cancer Biol Ther; 2009 Nov; 8(21):2073-80. PubMed ID: 19783898
[TBL] [Abstract][Full Text] [Related]
34. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.
Meng J; Dai B; Fang B; Bekele BN; Bornmann WG; Sun D; Peng Z; Herbst RS; Papadimitrakopoulou V; Minna JD; Peyton M; Roth JA
PLoS One; 2010 Nov; 5(11):e14124. PubMed ID: 21124782
[TBL] [Abstract][Full Text] [Related]
35. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
